Brokers Offer Predictions for KROS Q3 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Research analysts at Wedbush issued their Q3 2024 earnings per share estimates for shares of Keros Therapeutics in a research report issued on Monday, November 4th. Wedbush analyst Y. Zhong expects that the company will earn ($1.31) per share for the quarter. Wedbush has a “Outperform” rating and a $84.00 price objective on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.90) per share. Wedbush also issued estimates for Keros Therapeutics’ Q4 2024 earnings at ($1.36) EPS, FY2024 earnings at ($5.14) EPS, Q1 2025 earnings at ($1.41) EPS, Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.25) EPS, FY2025 earnings at ($5.32) EPS, FY2026 earnings at ($5.16) EPS, FY2027 earnings at ($5.57) EPS and FY2028 earnings at ($4.66) EPS.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The firm’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.33) earnings per share.

Other analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research report on Thursday. Bank of America decreased their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Scotiabank assumed coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price for the company. Guggenheim assumed coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 target price for the company. Finally, Jefferies Financial Group started coverage on shares of Keros Therapeutics in a research note on Tuesday. They issued a “buy” rating for the company. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $88.89.

Keros Therapeutics Stock Up 1.1 %

KROS opened at $67.17 on Thursday. Keros Therapeutics has a 12 month low of $27.31 and a 12 month high of $73.00. The company has a fifty day simple moving average of $57.30 and a 200 day simple moving average of $51.99. The stock has a market cap of $2.52 billion, a P/E ratio of -13.09 and a beta of 1.23.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 22.90% of the stock is currently owned by insiders.

Institutional Trading of Keros Therapeutics

A number of institutional investors have recently modified their holdings of KROS. KBC Group NV lifted its stake in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares in the last quarter. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics during the 3rd quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Keros Therapeutics during the 2nd quarter valued at approximately $128,000. Finally, Ameritas Investment Partners Inc. lifted its stake in Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after purchasing an additional 324 shares in the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.